GlassScriptPhysician profile
Gary K Bockhold
NPI 1528159738
$1,140.25
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $227 · 2021: $417.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $302.93 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $142.87 | 2020-2021 | |
| Dompe US, INC. | $122.85 | 2021 | |
| Glaukos Corporation | $122.16 | 2019 | |
| Aerie Pharmaceuticals, INC. | $122.06 | 2019 | |
| Shire North American Group INC | $109.08 | 2019 | |
| Lombart Brothers, INC. | $92.71 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $62.40 | 2019-2021 | |
| Coopervision INC. | $26.81 | 2019 | |
| Akorn, INC. | $18.81 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.57 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bockhold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.